Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […]